Molecular signature for HCC: Role in predicting outcomes after liver transplant and selection for potential adjuvant treatment

Current Opinion in Organ Transplantation

Volumn 15, Issue 3, 2010, Pages 277-282

  Schmidt, Carl ^a   Marsh, J Wallis ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Fractional allelic imbalance; Genomics; Hepatocellular carcinoma; Liver transplantation; Milan criteria

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE INHIBITOR S 1; DOXORUBICIN; ENZYME INHIBITOR; FLUOROURACIL; GEMCITABINE; GLYPICAN 3; IODINATED POPPYSEED OIL; IODINE 131; MITOMYCIN C; UNCLASSIFIED DRUG;

ALLELIC IMBALANCE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENOMICS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953285096     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328339837b     Document Type: Review

References (38)

1. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
2. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88:538-543.
3. Marsh JW, Dvorchik I. Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?: yes. J Hepatol 2005; 43:558-562.
4. Henry L, Lavabre-Bertrand T, Vercambre L, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 2009; 58:833-838.
5. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4387 tissue samples. Am J Clin Pathol 2008; 129:899-906.
6. Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. J Am Med Assoc 2008; 299:53-60.
7. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143:182-188; discussion 188.
8. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080-1086.
9. Schwartz ME, D'Amico F, Vitale A, et al. Liver transplantation for hepatocellular carcinoma: are the Milan criteria still valid? Eur J Surg Oncol 2008; 34:256-262.
10. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-1403.
11. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10:35-43.
12. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003; 9:664-671.
13. Schwartz M, Dvorchik I, Roayaie S, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008; 49:581-588.
14. Dvorchik I, Schwartz M, Fiel MI, et al. Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 2008; 14:443-450.
15. Braconi C, Meng F, Swenson E, et al. Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer 2009; 115:3738-3748.
16. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13:1775-1782.
17. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633-638.
18. Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95:611-619.
19. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.
20. Finkelstein SD, Marsh W, Demetris AJ, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37:871-879.
21. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91:181-184.
22. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32:1757-1762.
23. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34:55-60.
24. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophillymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250:141-151.
25. Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008; 206: 281-291.
26. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247:43-48.
27. Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995; 221:734-741; discussion 731-743.
28. Hsieh CB, Chou SJ, Shih ML, et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008; 34:906-910.
29. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multicentre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19:288-294.
30. Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008; 15:3169-3177.
31. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235:533-539.
32. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and metaanalysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96:975-981.
33. Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5:1909-1913.
34. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361:1437-1447.
35. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
36. Nakamura M, Nagano H, Marubashi S, et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112:1765-1771.
37. Hoffmann K, GlimmH, Radeleff B, et al. Prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation: HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8:349.
38. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13:5847-5854.